Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Official title

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Study identification

NCT ID

NCT03678025

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

SWOG Cancer Research Network

Network

Enrollment

1,273 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

Male

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 23, 2018

Primary completion

Mar 31, 2028

Completion

Sep 30, 2031

Last update posted

Sep 10, 2025

2018 – 2031

United States locations

U.S. sites

334

U.S. states

43

U.S. cities

256

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.